We are live on
!
Find out more
SCM
Soleus Capital Management Portfolio holdings
AUM
$2.47B
1-Year Est. Return
115.63%
This Fund
S&P 500
This Quarter
Est. Return
+11.18%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$900M
AUM Growth
-$66.1M
(-6.9%)
Cap. Flow
-$123M
Cap. Flow
% of AUM
-13.72%
Top 10 Holdings %
Top 10 Hldgs %
42.92%
Holding
115
New
38
Increased
27
Reduced
28
Closed
14
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teva Pharmaceuticals
TEVA
|
+$34.5M |
| 2 |
United Therapeutics
UTHR
|
+$23.6M |
| 3 |
Humana
HUM
|
+$19.6M |
| 4 |
SkinHealth Systems
SKIN
|
+$14.5M |
| 5 |
Seres Therapeutics
MCRB
|
+$11.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$51.8M |
| 2 |
EXAS
Exact Sciences
EXAS
|
+$30.2M |
| 3 |
Smith & Nephew
SNN
|
+$14.9M |
| 4 |
SI-BONE Inc
SIBN
|
+$10.6M |
| 5 |
ACLX
Arcellx
ACLX
|
+$9.41M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 96.82% |
| 2 | Consumer Staples | 2.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Axsome Therapeutics
AXSM
$10.9B
| $1.79M | 0.2% |
24,900
+4,200
| +20% | +$310K |
|
77
Acadia Pharmaceuticals
ACAD
$4.39B
| $1.58M | 0.18% |
66,000
-124,000
| -65% | -$2.76M |
|
78
Aclaris Therapeutics
ACRS
$772M
| $1.57M | 0.17% |
151,000
-98,000
| -39% | -$887K |
|
|
CERE
79
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $1.46M | 0.16% |
46,000
-109,000
| -70% | -$3.35M |
|
80
Liquidia Corp
LQDA
$7.46B
| $1.37M | 0.15% |
+175,000
| New | +$1.36M |
|
81
Mineralys Therapeutics
MLYS
$2.27B
| $1.31M | 0.15% |
76,817
-196,424
| -72% | -$2.94M |
|
82
Avita Medical
RCEL
$142M
| $1.28M | 0.14% |
+75,000
| New | +$1.1M |
|
83
Protagonist Therapeutics
PTGX
$8.51B
| $1.1M | 0.12% |
+39,800
| New | +$996K |
|
|
YMAB
84
DELISTED
Y-mAbs Therapeutics
YMAB
| $1.07M | 0.12% |
157,182
+70,000
| +80% | +$525K |
|
85
Immunocore
IMCR
$1.65B
| $983K | 0.11% |
+16,400
| New | +$936K |
|
|
ALPN
86
DELISTED
Alpine Immune Sciences Inc
ALPN
| $905K | 0.1% |
+88,073
| New | +$794K |
|
87
Viridian Therapeutics
VRDN
$2.13B
| $809K | 0.09% |
+34,000
| New | +$872K |
|
|
MORF
88
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $780K | 0.09% |
+13,600
| New | +$710K |
|
89
Immunic
IMUX
$192M
| $753K | 0.08% |
30,000
| – | – |
|
|
VTYX
90
DELISTED
Ventyx Biosciences
VTYX
| $699K | 0.08% |
+21,300
| New | +$734K |
|
91
Rhythm Pharmaceuticals
RYTM
$7.05B
| $637K | 0.07% |
+38,600
| New | +$697K |
|
92
Pliant Therapeutics
PLRX
$64.4M
| $607K | 0.07% |
+33,500
| New | +$793K |
|
93
Xilio Therapeutics
XLO
$59.5M
| $595K | 0.07% |
16,210
| – | – |
|
94
Pulmonx
LUNG
$89.5M
| $538K | 0.06% |
41,000
-30,000
| -42% | -$367K |
|
|
ADVM
95
DELISTED
Adverum Biotechnologies
ADVM
| $509K | 0.06% |
+32,000
| New | +$336K |
|
96
Celldex Therapeutics
CLDX
$2.96B
| $461K | 0.05% |
+13,600
| New | +$458K |
|
|
VRNA
97
DELISTED
Verona Pharma
VRNA
| $459K | 0.05% |
+21,700
| New | +$463K |
|
98
Indivior Pharmaceuticals
INDV
$4.42B
| $443K | 0.05% |
+18,624
| New | +$427K |
|
99
Travere Therapeutics
TVTX
$5.11B
| $332K | 0.04% |
21,600
-213,000
| -91% | -$3.87M |
|
|
FNA
100
DELISTED
Paragon 28, Inc.
FNA
| $177K | 0.02% |
10,000
-194,018
| -95% | -$3.49M |
|
Similar funds
TW
M
SG
BL
FFA
GWM
Q
SIM
Soleus Capital Management's Q2 2023 Portfolio in Review
As of Q2 2023, Soleus Capital Management held 115 positions worth $900M, down 6.9% from $966M the previous quarter. Its ten largest holdings account for 43% of the portfolio.
Soleus Capital Management withdrew a net $123M in Q2 2023, closing 14 positions and reducing 28 holdings. Its most notable exit was IVERIC bio, Inc. Common Stock, an estimated $51.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 81% a quarter earlier, followed by Consumer Staples.
Against the trend, Soleus Capital Management opened a new position in Teva Pharmaceuticals worth $32M.
- Soleus Capital Management's largest Q2 2023 buy was Teva Pharmaceuticals: 4,250,000 shares worth $32M.
- Soleus Capital Management added most to United Therapeutics in Q2 2023, an estimated $23.6M increase.
- Soleus Capital Management's biggest Q2 2023 reduction was Exact Sciences, cutting an estimated $30.2M.
- Soleus Capital Management fully exited IVERIC bio, Inc. Common Stock in Q2 2023, selling an estimated $51.8M.
- Soleus Capital Management's ten largest holdings make up 43% of its $900M portfolio in Q2 2023.
- Soleus Capital Management opened 38 new positions and closed 14 in Q2 2023.
- Soleus Capital Management's portfolio value fell 6.9% quarter-over-quarter to $900M.
Based on Soleus Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.